Latest Breaking News On - Franziska burianek - Page 1 : vimarsana.com

Immunic, Inc (NASDAQ:IMUX) Q4 2023 Earnings Call Transcript

Immunic, Inc. beats earnings expectations. Reported EPS is $-0.48, expectations were $-0.51.

United statesNoord hollandGeertr dhaensFranziska burianekBob foxDaniel vittJessica breuGlenn whaleyImmunic incAssembly conferenceAssociation of european celiac societyAmsterdam university medical centerCall transcript februaryFourth quarterYear endVice president

Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for.

Franziska burianekEdna kaplanDaniel vittPaula schwartzJessica breuExchange commissionRx communications groupImmunic incUnited european gastroenterology weekChief executive officerHuman trialBarrier regenerationSenior medical directorModerated postersPoster stagePrivate securities litigation reform act

EQS-News: Immunic, Inc : Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

EQS-News: Immunic, Inc : Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Paula schwartzEdna kaplanFranziska burianekDaniel vittJessica breuRx communications groupExchange commissionDistribution servicesImmunic incPresents data from phaseClinical trialCeliac diseaseUnited european gastroenterology weekChief executive officerHuman trialBarrier regeneration

Immunic to Participate in Scientific Conferences in October

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for.

United statesNoord hollandBruxelles capitaleDarius jean namdjouGeertr dhaensJessica breuEdna kaplanPaula schwartzFranziska burianekRobertj foxRx communications groupExchange commissionAmsterdam university medical centersMellen centerImmunic incRegulatory affairs operations

EQS-News: Immunic to Participate in Scientific Conferences in October

Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific Conferences in October 04.10.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Scientific Conferences in October NEW YORK, October 4, 2023 – I.

Bruxelles capitaleUnited statesNoord hollandEdna kaplanGeertr dhaensJessica breuRobertj foxFranziska burianekDarius jean namdjouPaula schwartzHead of regulatory affairsRegulatory affairs operationsRx communications groupAmsterdam university medical centersGlobal pharmaceutical regulatory affairs summitNeurologic institute